Online inquiry

IVTScrip™ mRNA-Anti-SDC1, BT-062(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ4835MR)

This product GTTS-WQ4835MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets SDC1 gene. The antibody can be applied in Multiple myeloma (MM) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Chimeric
RefSeq NM_001006946.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 6382
UniProt ID P18827
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-SDC1, BT-062(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ4835MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ12837MR IVTScrip™ mRNA-Anti-FZD10, ONC-005(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ONC-005
GTTS-WQ540MR IVTScrip™ mRNA-Anti-ERBB2, 4D5-8(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA 4D5-8
GTTS-WQ4199MR IVTScrip™ mRNA-Anti-IL2RA, BIIB019(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BIIB019
GTTS-WQ12653MR IVTScrip™ mRNA-Anti-RSPO3, OMP-131R10(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA OMP-131R10
GTTS-WQ15723MR IVTScrip™ mRNA-Anti-S, VIR-7831(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA VIR-7831
GTTS-WQ4040MR IVTScrip™ mRNA-Anti-IL23A, BI 655066(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BI 655066
GTTS-WQ3365MR IVTScrip™ mRNA-Anti-MS4A1, AT-004(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AT-004
GTTS-WQ10501MR IVTScrip™ mRNA-Anti-APP, LY3002813(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA LY3002813
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW